Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Trinity Bivalacqua MD, PhD

Trinity J. Bivalacqua MD, PhD

Professor of Urology and Oncology, Division of Urology, Perelman Center for Advanced Medicine, University of Pennsylvania; Director of Urology Oncology and GU Service Line, Abramson Cancer Center, Philadelphia, Pennsylvania

Trinity J. Bivalacqua M.D. Ph.D. is a Professor of Urology and Oncology at the Perelman Center for Advanced Medicine, University of Pennsylvania, Division of Urology and the Director of Urology Oncology and GU Service Line in the Abramson Cancer Center.  He received his undergraduate degree, medical and PhD (pharmacology) graduate degrees from Tulane University and completed a Urology residency at the Johns Hopkins Hospital.  He completed a Urology Care Foundation Post-Doctoral Fellowship.  He is actively involved in resident and medical student education.  He has a clinical sub-specialty interest in prostate and bladder cancer as well as sexual dysfunction.  He has a basic translational research lab focusing on urothelial cancer and regenerative medicine which is supported by peer-reviewed grant funding.  He is a recipient of the AUA Rising Start Award, a member of the AUA Leadership Program, and was awarded the Gold Cystoscope from the AUA.  He is actively involved in committees for the Society of Urologic Oncology (SUO), Sexual Medicine Society of North America (SMSNA), and the Bladder Cancer Advocacy Network (BCAN).

Recent Contributions to PracticeUpdate:

  1. Relationship Between the Number of Lymph Nodes Dissected and Prognosis in Patients With MIBC in the Era of Neoadjuvant Chemotherapy
  2. Role of Complete TURBT Before Radical Cystectomy in Patients With Organ-Confined Bladder Cancer
  3. Adjuvant Chemotherapy vs Observation Following Radical Cystectomy for Locally Advanced Urothelial Carcinoma of the Bladder
  4. Intracorporeal vs Extracorporeal Neobladder After Robot-Assisted Radical Cystectomy
  5. Role of Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Radical Prostatectomy
  6. Acceptance and Commitment Therapy to Increase Adherence to Penile Injection Therapy–Based Rehabilitation After Radical Prostatectomy
  7. Predictors of Treatment Success After Collagenase Clostridium histolyticum Injection for Peyronie's Disease
  8. Urinary Cytology Underperforms in Hematuria Investigations
  9. Effect of Urinary Cytology for Detecting Recurrence in Remnant Urothelium After Radical Cystectomy
  10. Investigation of Changes in Penile Length After Radical Prostatectomy

Recently Updated